ChEMBL ligand: CHEMBL49302 (LY-223982, LY-333982)
D3 receptor/Dopamine D3 receptor in Human [ChEMBL: CHEMBL234] [GtoPdb: 216] [UniProtKB: P35462] There should be some charts here, you may need to enable JavaScript!
BLT1 receptor/Leukotriene B4 receptor 1 in Human [ChEMBL: CHEMBL3911] [GtoPdb: 267] [UniProtKB: Q15722] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
D3 receptor/Dopamine D3 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL234] [GtoPdb: 216] [UniProtKB: P35462]
ChEMBL	PDSP Secondary Binding target: DRD3 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.	B	5.71	pKi	1958.39	nM	Ki	EUbOPEN Chemogenomics Library - PDSP Secondary Binding
BLT1 receptor/Leukotriene B4 receptor 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3911] [GtoPdb: 267] [UniProtKB: Q15722]
GtoPdb	-	-	7.9	pKd	13	nM	Kd	J Pharmacol Exp Ther (1992) 262: 80-9 [PMID:1320692]
ChEMBL	Binding affinity against Leukotriene B4 receptor on intact differentiated U-937 cells in competitive binding assay with [3H]LTB4	B	6.44	pKi	360	nM	Ki	J Med Chem (1993) 36: 3333-3340 [PMID:8230123]
ChEMBL	Compound was evaluated for inhibition of binding of [3H]LTB4 to LTB4 receptor in guinea-pig lung membranes	B	8.11	pKi	7.8	nM	Ki	Bioorg Med Chem Lett (1993) 3: 1981-1984
ChEMBL	Inhibition of LTB4-induced elastase release in human polymorphonuclear leukocytes	F	6	pIC50	1000	nM	IC50	J Med Chem (1992) 35: 4315-4324 [PMID:1333012]
ChEMBL	Inhibition of specific binding of [3H]LTB4 ( 0.1 nM) to LTB4 receptor on intact human neutrophils	B	7.88	pIC50	13.2	nM	IC50	J Med Chem (1993) 36: 1726-1734 [PMID:8389876]
ChEMBL	Inhibition of specific binding of [3H]LTB4 to Leukotriene B4 receptor in human neutrophils	B	7.88	pIC50	13.2	nM	IC50	J Med Chem (1990) 33: 2807-2813 [PMID:2170648]
ChEMBL	Compound was tested for inhibitory activity against human neutrophil LTB4 receptor binding	F	7.89	pIC50	13	nM	IC50	J Med Chem (1996) 39: 2629-2654 [PMID:8709092]
ChEMBL	In vitro antagonistic activity towards LTB4 receptor was evaluated by inhibition of binding of [3H]LTB4 to human neutrophils	B	7.89	pIC50	13	nM	IC50	Bioorg Med Chem Lett (1993) 3: 1981-1984
ChEMBL	Antagonistic activity against human polymorphonuclear (PMN) LTB4 receptor	F	7.92	pIC50	12	nM	IC50	J Med Chem (1992) 35: 4253-4255 [PMID:1331462]
ChEMBL	Binding affinity to leukotriene B4 receptor on intact human PMNs by displacing radioligand [3H]LTB4	B	7.92	pIC50	12	nM	IC50	J Med Chem (1994) 37: 3327-3336 [PMID:7932560]
ChEMBL	Inhibitory concentration against leukotriene receptor B4 (LTB4) in human polymorphonuclear cells (PMNs)	B	7.92	pIC50	12	nM	IC50	J Med Chem (1993) 36: 2703-2705 [PMID:8410983]
ChEMBL	Inhibition of [3H]-LTB4 binding to Leukotriene B4 receptor in the human polymorphonuclear leukocytes.	B	8.46	pIC50	3.5	nM	IC50	J Med Chem (1992) 35: 4315-4324 [PMID:1333012]
ChEMBL	Inhibition of [3H]LTB4 binding to Leukotriene B4 receptor in the human polymorphonuclear leukocytes	B	8.46	pIC50	3.5	nM	IC50	J Med Chem (1992) 35: 4306-4314 [PMID:1333011]
ChEMBL	Inhibition of [3H]LTB4 binding to Leukotriene B4 receptor in the guinea pig spleen membranes	B	8.7	pIC50	2	nM	IC50	J Med Chem (1992) 35: 4306-4314 [PMID:1333011]
ChEMBL	Inhibition of [3H]LTB4 binding to Leukotriene B4 receptor in the guinea pig spleen membranes.	B	8.7	pIC50	2	nM	IC50	J Med Chem (1992) 35: 4315-4324 [PMID:1333012]
ChEMBL	Inhibition of binding of [3H]LTB4 to receptor on nonradioactive LTB4	B	8.72	pIC50	1.9	nM	IC50	J Med Chem (1993) 36: 1726-1734 [PMID:8389876]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]